CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), targeting programmed death-1 (PD-1) and its ligand programmed death ligand-1 (PDL1), are efficient drugs in advanced non–small-cell lung cancer (NSCLC) [1–4].